Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III –IV melanoma

ConclusionsIn this final planned OPTiM analysis, talimogene laherparepvec continued to result in improved longer-term efficacy versus GM-CSF and remained well tolerated. The final analysis also confirms that talimogene laherparepvec was associated with durable CRs that were associated with prolonged survival.Trial registrationClinicalTrials.gov identifier:NCT00769704.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research